SCHEMBL21669247

SCHEMBL21669247

CCOC(O)C(Cc1ccc(OC(=O)CCS(=O)(=O)O)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.46
PPARA Q07869 1/20 0.46
ABCB1 P08183 1/20 0.38
KLK5 Q9Y337 2/20 0.38
PTPRB P23467 7/20 0.37
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
BCL2 P10415 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
AGTR1 P30556 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21669235 0.91 PPARG (0.45) PPARGPPARAABCB1KLK5PTPRB
SCHEMBL21669315 0.90 KLK5 (0.41) PPARGPPARAABCB1KLK5PTPRB
SCHEMBL21669324 0.89 KMT2A (0.39) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL21668915 0.89 PPARG (0.41) PPARGPPARAABCB1KLK5PTPRB
SCHEMBL21669260 0.87 KMT2A (0.39) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL24282726 0.85 KMT2A (0.38) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL21669232 0.84 PPARG (0.39) PPARGPPARAABCB1ALDH1A1LMNA
SCHEMBL24282891 0.84 TRPM8 (0.44) PPARGPPARAITGB3ITGA2BATM
SCHEMBL21669238 0.82 KMT2A (0.36) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL21669303 0.82 KLK5 (0.41) PPARGPPARAABCB1KLK5PTPRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829568-B1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-09-06 EP disclosed
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2022-03-24 US disclosed
WO-2020028348-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. (US) 2020-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 PPARG 571/4885PPARA 226/4885ABCB1 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.